Mesoporous Semi‐Permeable Flexible Polyurethane Membranes: Advancing Bioartificial Pancreas Design for Type 1 Diabetes Treatment
Macromolecular Rapid Communications · 2025
DOI: 10.1002/marc.202500049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Macromolecular Rapid Communications, 2025. Verfasst von Bryan Gross und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Chimie et Procédés pour l'Energie, l'Environnement et la Santé, ICPEES UMR 7515, CNRS, Université de Strasbourg, Ecole Européenne de Chim…. Hauptthemen laut MEDLINE: Polyurethanes, Diabetes Mellitus, Type 1, Membranes, Artificial, Pancreas, Artificial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BPI France, Agence Nationale de la Recherche.
Themen: Diabetes mellitus
Abstract (Originalsprache)
This study reports the development of elastomeric mesoporous polyurethane (PU) membranes for bioartificial pancreas applications in type 1 diabetes treatment. The membranes are designed to exhibit semi‐permeable properties, enabling insulin diffusion while restricting larger immune molecules, such as immunoglobulin G (IgG). Although electrospinning is a widely used technique for fabricating porous membranes for controlled drug release, it typically results in an average pore size on the order of few micrometers, which is two orders of magnitude larger than the mesoporous scale required. In this work, a green‐electrospinning process using waterborne PU suspension and poly(ethylene oxide) (PEO) is employed, followed by thermal annealing and washing steps. The resulting membranes exhibit a controlled pore size in the mesoporous range (≈20 nm measured by capillary flow porometry). Diffusion tests confirmed selective permeability, with a recovery rate of 25% for insulin and a recovery rate below 5% for IgG, meeting therapeutic needs. In vivo characterizations show no degradation and good biocompatibility of the membranes without chronic inflammation. Moreover, mechanical characterization demonstrates the membranes' flexibility and strength, making them suitable for minimally invasive surgical implantation. These findings underscore the potential of PU membranes for long‐term biomedical applications, addressing critical challenges in permeability and mechanical stability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de Chimie et Procédés pour l'Energie, l'Environnement et la Santé, ICPEES UMR 7515, CNRS, Université de Strasbourg, Ecole Européenne de Chimie, Polymères et Matériaux, 25 rue Becquerel, Strasbourg, Cedex 267087…
- Defymed, 9 rue Albert Calmette, Strasbourg, 67200, France.
- Institut National de la Santé et de la Recherche Médicale, UMR_S 1121, Université de Strasbourg, Faculté de Chirurgie Dentaire, Strasbourg, France.
ORCID-Profile: Emeline Lobry, Séverine Sigrist, Elisa Maillard, Jordan Magisson, Anne Hébraud, Guy Schlatter
Förderung
- BPI France
- Agence Nationale de la Recherche
Zitieren
APA
Gross, B., Lobry, E., Sigrist, S., Maillard, E., Magisson, J., Burcez, C. T., Pires, M., Hébraud, A., & Schlatter, G. (2025). Mesoporous Semi‐Permeable Flexible Polyurethane Membranes: Advancing Bioartificial Pancreas Design for Type 1 Diabetes Treatment. Macromolecular Rapid Communications. https://doi.org/10.1002/marc.202500049
Vancouver
Gross B, Lobry E, Sigrist S, Maillard E, Magisson J, Burcez CT, et al. Mesoporous Semi‐Permeable Flexible Polyurethane Membranes: Advancing Bioartificial Pancreas Design for Type 1 Diabetes Treatment. Macromolecular Rapid Communications. 2025. doi:10.1002/marc.202500049
BibTeX
@article{Gross2025,
author = {Gross, Bryan and Lobry, Emeline and Sigrist, Séverine and Maillard, Elisa and Magisson, Jordan and Burcez, Charles-Thibault and Pires, Manuel and Hébraud, Anne and Schlatter, Guy},
title = {Mesoporous Semi‐Permeable Flexible Polyurethane Membranes: Advancing Bioartificial Pancreas Design for Type 1 Diabetes Treatment},
journal = {Macromolecular Rapid Communications},
year = {2025},
doi = {10.1002/marc.202500049}
}
EUVIMED